|
Pharmacogenetics revisits bevacizumab in breast cancer patients: An ancillary analysis of the UCBG trial COMET—A French multicentric prospective study from R&D UNICANCER. |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Hospira; Janssen; Roche |
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Hospira; OBI Pharma; Roche |
Research Funding - Amgen (Inst); HalioDx (Inst); Teva (Inst) |
Travel, Accommodations, Expenses - Pfizer; Pfizer; Pierre Fabre; Roche |
|
|
No Relationships to Disclose |
|
|
|
|
|
Honoraria - AstraZeneca; NanoString Technologies; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Novartis; Pfizer |
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); Novartis; pfizer (Inst); Pierre Fabre (Inst) |
Travel, Accommodations, Expenses - Novartis; pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Marie-Christine Etienne-Grimaldi |
No Relationships to Disclose |